Related Experiment Video
Updated: Jul 3, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Postoperative adjuvant chemotherapy in surgically staged grade 3 endometrial cancer
Nobuhiro Takeshima1, Tsuyoshi Ota, Kohei Omatsu
1Department of Gynecology, Cancer Institute Hospital, Tokyo, Japan. nobuhiro.takeshima@jfcr.or.jp
Background:
The effectiveness of postoperative adjuvant chemotherapy for surgically staged grade 3 endometrial cancer was investigated.
Patients And Methods:
Sixty-three consecutive patients with grade 3 endometrial cancer (49 with surgical stage I-II disease and 14 with stage III disease) were treated surgically. Postoperatively, 40 patients (63.5%) were treated with a chemotherapy regimen consisting of ifosfamide, epiadriamycin, and cisplatin scheduled for 3-5 cycles. No patient underwent radiotherapy.
Results:
Recurrence developed in 8 out of the 63 patients, all within two years. Six of the 8 recurrences were found to be extrapelvic lesions. Recurrences occurred predominantly at distant sites in the absence of pelvic radiation. Estimated 5-year disease-free survival rates were 89.8% for patients with surgical stage I-II disease, 78.6% for those with surgical stage III disease, and 87.3% overall.
Conclusion:
The current study suggests the potential role of adjuvant chemotherapy alone in grade 3 endometrial cancer.
